Last $12.39 USD
Change Today -0.41 / -3.20%
Volume 272.4K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

osiris therapeutics inc (OSIR) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/14/13 - $27.40
52 Week Low
06/21/13 - $10.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

osiris therapeutics inc (OSIR) Related Businessweek News

No Related Businessweek News Found

osiris therapeutics inc (OSIR) Details

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing products to treat medical conditions in wound care, orthopedic, and sports medicine markets. The company’s stem cell drug, remestemcel-L, is indicated for graft versus host disease. Its products include Grafix and Ovation for acute and chronic wounds; Cartiform, a viable cartilage mesh for cartilage repair; and OvationOS, a viable bone matrix. It markets and distributes its products directly to hospitals and clinics, as well as through a network of distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

70 Employees
Last Reported Date: 03/31/14
Founded in 1992

osiris therapeutics inc (OSIR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.8K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $227.3K
Compensation as of Fiscal Year 2013.

osiris therapeutics inc (OSIR) Key Developments

Osiris Therapeutics, Inc. Announces Executive Changes

Osiris Therapeutics, Inc. announced on March 31, 2014 that Michelle LeRoux Williams, who has served as it's Chief Scientific Officer since February 2009, tendered her resignation, effective April 15, 2014. Alla Danilkovitch has been promoted to Vice President of Research and Development, and she will lead innovation and R&D at Osiris. Dr. Danilkovitch has been with Osiris since April 2003 as it's principal scientist and has been integral to the development of it's products Osteocel, Prochymal, Grafix, OvationOS and Cartiform.

Osiris Therapeutics Appoints Therésa K. Dixon as General Manager of Market Access and Reimbursement

Osiris Therapeutics, Inc. announced the appointment of Therésa K. Dixon, to General Manager, Market Access and Reimbursement, reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. She served as Vice President of Government Affairs & Health Economics and a member of the senior leadership team at Advanced BioHealing, Inc., (ABH) which was acquired by Shire in 2011.

Osiris Therapeutics, Inc. announced delayed annual 10-K filing

On 03/17/2014, Osiris Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSIR:US $12.39 USD -0.41

OSIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.73 USD +0.10
BioTime Inc $2.78 USD +0.05
Cytori Therapeutics Inc $2.34 USD -0.01
Geron Corp $1.94 USD -0.03
NeoStem Inc $6.46 USD -0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation OSIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book 5.2x
Price/Cash Flow 10.2x
TEV/Sales 15.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OSIRIS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at